Mirikizumab (Omvoh) improved outcomes in patients with moderately-to-severely active Crohn's disease with previous failure to ...

Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors ...

Discover how nicotinamide riboside reduces airway inflammation in COPD patients by lowering IL-8 levels and enhancing ...

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...

IMUNON (IMNN) announced the outcome of its recent End-of-Phase 2 in-person meeting with the U.S. Food and Drug Administration, FDA, supporting ...

Mural Oncology (NASDAQ:MURA – Get Free Report) is one of 1,048 public companies in the “Pharmaceutical preparations” industry ...

The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...

The Food and Drug Administration (FDA) has approved a new presentation of Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ® (ustekinumab), expanding the product’s indications to include ...

The researchers utilized a Fra-2 transgenic mouse model that encompasses many of the features of systemic sclerosis in humans, including spontaneous systemic inflammation and fibrosis in the lungs, ...

The drug candidates comprise modified versions of recombinant human interleukin-18 with the patent effective till June 2044. SON-1411 is a bifunctional fusion protein that combines IL-18 with ...

National register data from patients diagnosed with RA who began treatment with TNF inhibitors, rituximab, abatacept, interleukin (IL)-6 inhibitors, or JAK inhibitors between 2017 and 2019 were ...

A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) -- a potent immune-boosting protein that holds promise for cancer treatment ...